Futility findings by the data safety monitoring board from the phase II ALPINE pancreatic cancer trial with anti-Notch 2/3 therapy tarextumab cast into doubt the predictive value of phase Ib studies with similar Notch-targeting candidates, and Oncomed Pharmaceuticals Inc.